A recently published report summarizes the biomarker targets in both hematological and solid malignancies for CAR T cell therapy and discusses potential new biomarker target. A biomarker is an integral part ofRead More…
Recently, MaxCyte announced that the company’s chimeric antigen receptor (CAR) cell therapy for the treatment of solid tumors based on non-viral messenger RNA (mRNA) technology has been approved by the Food andRead More…
Chimeric antigen receptor T cell (CAR-T) therapy is a novel cellular immunotherapy method that introduces chimeric antigen receptors and costimulatory molecules targeting specific targets into T cells by gene editing technology. TumorRead More…
Chimeric antigen receptor, or CAR, T cells have considerably improved cancer treatment outcomes for certain malignancies. CAR T cells are produced when T cells isolated from the patient are modified to targetRead More…